CompletedPhase 4

Paricalcitol Versus Calcitriol for the Management of Renocardiac Syndrome in Renal Transplant Patients

Netherlands, Russia109 participantsStarted 2009-10

Plain-language summary

We hypothesize that paricalcitol and calcitriol in dose-dependent manner are effective for the management of chronic allograft dysfunction (CAD), protection and repair of kidney and heart, management of chronic renocardiac syndrome (CRS). We assume that paricalcitol can have some advantages if compare with calcitriol or cholecalciferol due to absence of calcemic and phosphatemic complications alongside with great beneficial potential.

Who can participate

Age range40 Years – 75 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 40-75 * Male * History of chronic kidney disease and cardiorenal syndrome * Written informed consent Exclusion Criteria: * Female * Acute illness * Life-threat competitive illness * Mental disorders * Endocrinologic diseases (including diabetes mellitus, hyperparathyroidism, and other thyroid disorders) * Need for dialyses * Hypercalcemia * Concomitant use of hormone or cytokine medication * Participation to any drug-investigation during the previous 60 days as checked with VIP check

What they're measuring

CAD (Chronic Allograft Dysfunction) Degree

Timeframe: day 180 after Tx (transplantation)

Trial details

NCT IDNCT01265615

SponsorUral State Medical University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2010-04

Results submitted2010-12-27

View on ClinicalTrials.gov More Cardiorenal Syndrome trials